Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.3%

2 terminated out of 32 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

28%

9 trials in Phase 3/4

Results Transparency

25%

4 of 16 completed with results

Key Signals

4 with results89% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (3)
P 1 (5)
P 2 (5)
P 3 (8)
P 4 (1)

Trial Status

Completed16
Recruiting5
Active Not Recruiting5
Terminated2
Unknown2
Not Yet Recruiting2

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT01430494CompletedPrimary

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT07161037Phase 2RecruitingPrimary

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT06747572Active Not RecruitingPrimary

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT07535385RecruitingPrimary

RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY

NCT02127437Phase 3CompletedPrimary

Lanreotide In Polycystic Kidney Disease Study

NCT07074327Phase 1CompletedPrimary

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07022119Phase 1CompletedPrimary

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06594367CompletedPrimary

A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province

NCT07454174Not ApplicableRecruitingPrimary

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

NCT06714006Phase 1RecruitingPrimary

Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

NCT06786260Not ApplicableNot Yet RecruitingPrimary

Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT07355114Active Not RecruitingPrimary

Robotic vs Open Nephrectomy for ADPKD

NCT02925221CompletedPrimary

Canadian Medical Assessment of JINARC™ Outcomes Registry

NCT07260071RecruitingPrimary

Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease

NCT07181265Phase 1Not Yet RecruitingPrimary

Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects

NCT07016282Active Not RecruitingPrimary

Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study

NCT06345755Phase 1CompletedPrimary

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06289998Phase 2Active Not RecruitingPrimary

Study of Tamibarotene in Patients With ADPKD

NCT06688981Active Not RecruitingPrimary

Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease

NCT02964273Phase 3CompletedPrimary

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Scroll to load more

Research Network

Activity Timeline